Pharmacology of antimicrobials used in the treatment of serious Gram-positive bacteria infections;Farmacología de antimicrobianos utilizados en el tratamiento de las infecciones graves por bacterias grampositivas

Revista Espanola de Quimioterapia

Volumn 16, Issue 3, 2003, Pages 277-288

  Garcia Quetglas E ^a   Azanza Perea, J R ^a   Sadaba Diaz De Rada B ^a   Gil Aldea, I ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

Author keywords

Glycopeptides; Gram positive cocci; Oxazolidinone; Streptogramin

Indexed keywords

ANTIINFECTIVE AGENT; CYTOCHROME P450; DALFOPRISTIN; GLYCOPEPTIDE; LINEZOLID; OXAZOLIDINONE DERIVATIVE; QUINUPRISTIN; STREPTOGRAMIN; TEICOPLANIN; VANCOMYCIN;

ANEMIA; ANTIBACTERIAL ACTIVITY; ARTHRALGIA; BACTERIAL INFECTION; DIARRHEA; DISEASE SEVERITY; DRUG ACTIVITY; DRUG ADMINISTRATION ROUTE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG ELIMINATION; DRUG ERUPTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG TISSUE LEVEL; EXTRACELLULAR SPACE; EXTRAVASCULAR SPACE; GASTROINTESTINAL SYMPTOM; GRAM NEGATIVE BACTERIUM; HUMAN; INFLAMMATION; KIDNEY FAILURE; LEUKOPENIA; LIVER DISEASE; LIVER METABOLISM; MYALGIA; NAUSEA; NEPHROTOXICITY; PANCYTOPENIA; PRURITUS; REVIEW; SIDE EFFECT; STRUCTURE ANALYSIS; THROMBOCYTOPENIA; URINARY EXCRETION; VOMITING;

AGE FACTORS; ANTI-BACTERIAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; KIDNEY DISEASES; SEVERITY OF ILLNESS INDEX;

EID: 0344873674     PISSN: 02143429     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (68)

1. Vaqué, J. y grupo de trabajo EPINE 1990-1999. Evolución, de la prevalencia de las infecciones nosocomiales en los hospitales españoles. EPINE 1990-1999. Sociedad Española de Medicina Preventiva, Salud Pública e Higiene, Madrid 1998.
2. Jensen, A.G., Wachmann, C.H., Poulsen, K.B. y cols. Risk factors for hospital-acquired Staphylococcus aureus bacteremia. Arch Intern Med 1999; 159: 1437-1444.
3. Pittet, D., Tarara, D., Wenzel, R.P. Nosocomial bloodstream infection in critically ill patients. Excess length of stay, extra costs, and attributable mortality. JAMA 1994; 271: 1598-1601.
4. García-Rodríguez, J.A., García Sánchez, E. El resurgimiento de los grampositivos: Razones, significado clínico y posibilidaddes de control. Rev Clin Esp 1997; 197 (Supl. 2): 3-11.
5. Cohen, M.L. Epidemiology of drug resistance. Implications for a post-antimicrobial era. Science 1992; 257: 1050-1055.
6. Levin, B.R., Antia, R., Berliner, E. y cols. Resistance to antimicrobial chemotherapy: A prescription for research and action. Am J Med Sci 1998; 315: 87-94.
7. Chopra, I., Hodgson, J., Metcalf, B., Poste, G. The search for antimicrobial agents effective against bacteria resistant to multiple antibiotics. Antimicrob Agents Chemother 1997; 41: 497-503.
8. Reynolds, P.E. Structure, biochemistry and mechanism of action of glycopeptide antibiotics. Eur J Clin Microbiol Infect Dis 1989; 8: 943-950.
9. Rodríguez Castilla, J., Buzo Sánchez L., Cameán Fernández M., Escudero Santos, I., Ávila Álvarez, J., Miguel del Corral, M. Glucopéptidos anfóteros en el tratamiento de cocos grampositivos multi-rresistentes. Ciencia Pharmacéutica 1993; 3: 129-136.
10. Nicas, T., Zeckel, M.L., Braun, D.K. Beyond vancomycin: New therapies to meet the challenge of glycopeptide resistance. Trends Microbiol 1997; 5: 240-249.
11. Aumercier, M., Bouhallab, S., Capmau, M.L., Le Goffic, F. RP 59500: A proposed mechanism for its bactericidal activity. J Antimicrob Chemother 1992; 30 (Suppl. A): 9-14.
12. Clemett, D., Markham, A. Linezolid. Drugs 2000; 59: 815-827.
13. Shinabarger, D.L., Marotti, K.R., Murray, R.W. y cols. Mechanism of action of oxazolidinones: Effects of linezolid and eperezolid on translation reactions. Antimicrob Agents Chemother 1997; 41: 2132-2136.
14. Swaney, S.M., Aoki, H., Ganoza, M.C., Shinabarger, D.L. The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria. Antimicrob Agents Chemother 1998; 42: 3251-3255.
15. ZYVOXID™ (linezolid injection, linezolid tablets, linezolid for oral suspension) [package insert]. Kalamazoo, Mi: Pharmacia Upjohn Company; April 2000.
16. Lamb, H.M., Figgitt, D.P., Faulds, D. Quinupristir/dalfopristin: A review of its use in the management of serious gram-positive infections. Drugs 1999; 58: 1061-1097.
17. Johnson, C.A., Taylor, C.A., Zimmerman, S.W. y cols. Pharmacokinetics of quinupristin-dalfopristin in continuous ambulatory peritoneal dialysis patients. Antimicrob Agents Chemother 1999; 43: 152-156.
18. Bergeron, M., Montay, G. The pharmacokinetics of quinupristin/dalfopristin in laboratory animals and in humans. J Antimicrob Chemother 1997; 39 (Suppl. A): 129-138.
19. Verbist, L., Tjandramaga, B., Hendrickx, B. y cols. In vitro activity and human pharmacokinetics of teicoplanin. Antimicrob Agents Chemother 1984; 26: 881-886.
20. Rowland, M. Clinical pharmacokinetics of teicoplanin. Clin Pharmacokinet 1990; 18: 184-209.
21. Boeckh, M., Lode, H., Borner, K., Höffken, G., Wagner, J., Koeppe, P. Pharmacokinetics and serum bactericidal activity of vancomycin alone and in combination with ceftazidime in healthy volunteers. Antimicrob Agents Chemother 1988; 32: 92-95.
22. Moellering, R.C. Pharmacokinetics of vancomycin. J Antimicrob Chemother 1984; 14 (Suppl. D): 43-52.
23. Delmee, M., Melin, P., Peetermans, W., Verbist, L., Verschraegen, G. Trearment of Clostridium difficile colitis. Summary of a round table held in Brussels on March, 3rd, 1994. Acta Clin Belg 1995; 50: 114-116.
24. Matzke, G.R. Vancomycin. En: Evans, W.E., Schentag, J.J., Jusko, W.J. (Eds.). Applied Pharmacokinetics. Principles of therapeutic drug monitoring. Applied Therapeutics, Vancouver 1992; 15/1-15/31.
25. Stalker, D.J., Wajszczuk, C.P., Batts, D.H. Linezolid safety, tolerance, and pharmacokinetics following oral dosing twice daily for 14,5 days. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto 1997; 23.
26. Welshman, I.R., Stalker, D.J., Wajszczuk, C.P. Assessment of absolute bioavailability and evaluation of the effect of food on oral bioavailability of linezolid. Antiinfect Drugs Chemother 1998; 1 (Suppl. 16): 54.
27. Assandri, A., Bernareggi, A. Binding of teicoplanin to human serum albumin. Eur J Clin Pharmacol 1987; 33: 191-195.
28. Krogstad, D.J., Moellering, R.C. Jr., Greenblatt, D.J. Single-dose kinetics of intravenous vancomycin. J Clin Pharmacol 1980; 20: 197-201.
29. Rotschafer, J.C., Crossley, K., Zaske, D.E., Mead, K., Sawchuk, R.J., Solem, L.D. Pharmacokinetics of vancomycin: Observations in 28 patients and dosage recommendations. Antimicrob Agents Chemother 1982; 22: 391-394.
30. Wilson, P.R. Clinical pharmacokinetics of teicoplanin. Clin Pharmacokinet 2000; 39: 167-183.
31. Cheung, R.P.F., DiPiro, J.T. Vancomycin: An update. Pharmacother 1986; 6: 153-164.
32. Lenders, H., Walliser, D., Schumann, K. Teicoplanin-spiegel in tonsillen-, schleimhaut-, knorpel-und knochengewebe. Fortschm Antimikrob Antineoplast Chemother 1991; 10-2: 119-121.
33. Massias, L., Dubois, C., de Lentdecker, P., Brodaty, O., Fischler, M., Farinotti, R. Penetration of vancomycin in uninfected sternal bone. Antimicrob Agents Chemother 1992; 36: 2539-2541.
34. Exner, K., Lang, E., Borsche, A., Lemperle, G. Efficacy, tolerability and pharmacokinetics of teicoplanin in patients undergoing breast surgery. Eur J Surg 1992; 567 (Suppl.): 33-38.
35. Kropec, A., Daschner, F.D. Penetration into tissues of various drugs active against Gram-positive bacteria. J Antimicrob Chemother 1991; 27 (Suppl. B): 9-15.
36. Martin, C., Bourget, P., Alaya, M. y cols. Teicoplanin in cardiac surgery: Intraoperative pharmacokinetics and concentrations in cardiac and mediastinal tissues. Antimicrob Agents Chemother 1997; 41: 1150-1155.
37. de Lalla, F., Novelli, A., Pellizzer, G. y cols. Regional and systemic prophylaxis with teicoplanin in monolateral and bilateral total knee replacement procedures: Study of pharmacokinetics and tissue penetration. Antimicrob Agents Chemother 1993; 37: 2693-2698.
38. Bergeron, M.G., Trottier, S., LePage, M.-C. y cols. A phase 1, open-label, single-dose study of blood and blister fluid pharmacokinetics of quinupristin/dalfopristin (Q/D, RP59500, Synercid). 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto 1997; 24.
39. Fantin, B., Leclercq, R., Ottaviani, M. y cols. In vivo activities and penetration of the two components of the streptogramin RP 59500 in cardiac vegetations of experimental endocarditis. Antimicrob Agents Chemother 1994; 38: 432-437.
40. Trostdorf, F., Reinert, R.R., Schmidt, H. y cols. Quinupristin/dalfopristin attenuates the inflammatory response and reduces the concentration of neuron-specific enolase in the cerebrospinal fluid of rabbits with experimental Streptococcus pneumoniae meningitis. J Antimicrob Chemother 1999; 43: 87-94.
41. Steer, J.A., Papini, R.P., Wilson, A.P. y cols. Pharmacokinetics of a single dose of teicoplanin in burn patients. J Antimicrob Chemother 1996; 37: 545-553.
42. Buniva, G., Del Favero, A., Bernareggi, A., Patoia, L., Palumbo, R. Pharmacokinetics of 14C-teicoplanin in healthy volunteers. J Antimicrob Chemother 1988; 21 (Suppl. A): 23-28.
43. Le-Liboux, A., Pasquier, O., Montay, G. Simultaneous high-performance liquid chromatographic determination of quinupristin, dalfopristin and their main metabolites in human plasma. J Chromatogr B Biomed Sci Appl 1998; 708: 161-168.
44. Wienkers, L.C., Wynalda, M.A., Feenstra, K.L., Slatter, J.G. In vitro metabolism of linezolid (PNU-100766): Lack of induction or inhibition of cytochrome P450 enzymes and studies on the mechanism of formation of the major human metabolite, PNU- 142586. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco (CA) 1999; A3.
45. 14C]PNU 100766 to healthy human volunteers. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego (CA) 1998; 17.
46. Klastersky, J., Daneu, D., Swings, G., Weerts, D. Antibacterial activity in serum and urine as a therapeutic guide in bacterial infections. J Infect Dis 1974; 129: 187-193.
47. Mahmood, I., Bailan, J.D. The pharmacokinetic principles behind scaling from preclinical results to phase 1 protocols. Clin Pharmacokinet 1999; 36: 1-11.
48. Li, R.C., Zhu, M., Schentag, J.J. Achieving an optimal outcome in the treatment of infections. The role of clinical pharmacokinetics and pharmacodynamics of antimicrobials. Clin Pharmacokinet 1999; 37: 1-16.
49. Bouvier d'Yvoire, M.J., Maire, P.H. Dosage regimens of antibacterials: Implications of a pharmacokinetic/pharmacodynamic model. Clin Drug Invest 1996; 11: 229-239.
50. Wilson, A.P.R., Grüneberg, R.N., Neu, H. A critical review of the dosage of teicoplanin in Europe and the USA. Int J Antimicrob Agents 1994; 4 (Suppl. 1): 1-30.
51. Leader, W.G., Chandler, M.TH., Castiglia, M. Pharmacokinetic optimisation of vancomycin therapy. Clin Pharmacokinet 1995; 28: 327-342.
52. Zimmermann, A.E., Katona, B.G., Plaisance, K.I. Association of vancomycin serum concentrations with outcomes in patients with gram-positive bacteremia. Pharmacotherapy 1995; 15: 85-91.
53. Cantú, T.G., Yamanaka-Yuen, N.A., Lietman, P.S. Serum vancomycin concentrations: Reappraisal of their clinical value. Clin Infect Dis 1994; 18: 533-543.
54. Moellering, R.C. Jr. Monitoring serum vancomycin levels: Climbing the mountain because it is there? Clin Infect Dis 1994; 19: 1180-1181.
55. Rybak, M.J., Lerner, S.A., Levine, D.P. y cols. Teicoplanin pharmacokinetics in intravenous drug abusers being treated for bacterial endocarditis. Antimicrob Agents Chemother 1991; 35: 696-700.
56. Tarral, E., Jehl, F., Tarral, A. y cols. Pharmacokinetics of teicoplaiiin in children. J Antimicrob Chemother 1988; 21 (Suppl. A): 47-51.
57. Asbury, W.H., Darsey, E.H., Rose, W.B., Murphy, J.E., Buffington, D.E., Capers, Ch.C. Farmacocinética de la vancomicina en neonatos y lactantes: Una evaluación retrospectiva. Ann Pharmacother (Ed. española) 1993; 1: 267-273.
58. Terragna, A., Ferrea, G., Loy, A. y cols. Pharmacokinetics of teicoplanin in pediatric patients. Antimicrob Agents Chemother 1988; 32: 1223-1226.
59. Kearns, G.L., Abdel-Rahman, S.M., Blumer, J.L. y cols. Single dose pharmacokinetics of linezolid in infants and children. Pediatr Infect Dis J 2000; 19: 1178-1184.
60. Lam, Y.W.F., Kapusnik-Uner, J.E., Sachdeva, M., Hackbarth, C., Gambertoglio, J.G., Sande, M.A. The pharmacokinetics of teicoplanin in varving degrees of renal function. Clin Pharmacother 1990; 47: 655-661.
61. Mundlein, E., von Baum, H., Geiss, H.K., Springsklee, M., Zeier, M., Andrassy, K. Life-threatening infection with multiresistant Staphylococcus epidermidis in a patient with end-stage renal disease: Cure with chloramphenicol and quinupristin/dalfopristin (RP 59500). Infection 1997; 25: 252-254.
62. Sahai, J., Healy, D.P., Shelton, M.J., Miller, J.S., Ruberg, J., Polk, R. Comparison of vancomycin and teicoplanin induced histamine release and red man syndrome. Antimicrob Agents Chemother 1990; 34: 765-769.
63. Stamatakis, M.K., Richards, J.G. Interaction between quinupristin/dalfopristin and cyclosporine. Ann Pharmacother 1997; 31: 576-578.
64. a4 (CYP3A4) inhibition by quinupristin/dalfopristin (Q/D): Interaction with nifedipine (N) in normal volunteers. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego (CA) 1998; 24.
65. Moellering, R.C., Linden, P.K., Reinhardt, J., Blumberg, E.A., Bompart, F., Talbot, G.H. The efficacy and safety, of quinupristin/dalfopristin for the treatment of infections caused by vancomycin-resistant Enterococcus faecium. Synercid Emergency-Use Study Group. J Antimicrob Chemother 1999; 44: 251-261.
66. Nichols, R.L., Graham, D.R., Barriere, S.L. y cols. Treatment of hospitalized patients with complicated gram-positive skin and skin structure infections: Two randomized, multicentre studies of quinupristin/dalfopristin versus cefazolin, oxacillin of vancomycin. Synercid Skin and Skin Structure Infection Group. J Antimicrob Chemother 1999; 44: 263-273.
67. Talbot, G.H., Zhu, G.R. Characterization of arthalgias/myalgias associated with quinupristin/dalfopristin (Synercid). Clin Infect Dis 1998;27:965.
68. Bompart, F., Dorr, M., Bekele, T. y cols. Overview of the safety and tolerability of quinupristin/dalfopristin (Synercid, RP 59500) in the global development program. 20th International Congress of Chemotherapy, Sydney 1997; 44-45.